Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
CLYM is expected to report earnings to fall 51.61% to -15 cents per share on August 19
Q2'25
Est.
$-0.15
Q1'25
Missed
by $0.16
The last earnings report on May 14 showed earnings per share of -31 cents, missing the estimate of -15 cents. With 1.01M shares outstanding, the current market capitalization sits at 93.93M.